Fennec Pharmaceuticals Inc. ~ Achieved Third Quarter 2024 Net Product Sales of $7.0 Million ~ ~ Increasing Momentum and Successful Reimbursement in the Adolescent and Young Adult (AYA) Segment ...

Stephens initiated coverage of Fennec (FENC) with an Overweight rating and $15 price target The firm is adding to its Biotechnology research coverage with a focus on targeted protein degradation ...

--Fennec Pharmaceuticals Inc., a specialty pharmaceutical company, today reported its financial results for the fiscal year ended December 31, 2024 and provided a business update. We are seeing ...

RESEARCH TRIANGLE PARK, N.C., June 03, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (the “Company”) (NASDAQ:FENC) (TSX:FRX) today announced that the nominees listed in the management ...

Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Q3 2024 Earnings Conference Call November 9, 2024 8:30 AM ETCompany Participants. Robert Andrade - Chief Financial Officer Jeff Hackman - Chief Executive ...